Legal & General Group Plc Decreases Stake in Cytokinetics, Incorporated $CYTK

Posted by George Bondi on Jun 4th, 2026

Legal & General Group Plc reduced its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 6.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 168,586 shares of the biopharmaceutical company’s stock after selling 11,064 shares during the period. Legal & General Group Plc’s holdings in Cytokinetics were worth $10,712,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in CYTK. Woodline Partners LP boosted its position in shares of Cytokinetics by 676.1% during the 3rd quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company’s stock worth $90,559,000 after purchasing an additional 1,435,422 shares in the last quarter. Deep Track Capital LP boosted its position in shares of Cytokinetics by 17.8% during the 3rd quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock worth $236,328,000 after purchasing an additional 650,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of Cytokinetics by 151,987.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 565,765 shares of the biopharmaceutical company’s stock worth $35,949,000 after purchasing an additional 565,393 shares in the last quarter. Foresite Capital Management IV LLC purchased a new stake in shares of Cytokinetics during the 3rd quarter worth $25,188,000. Finally, Rosalind Advisors Inc. purchased a new stake in shares of Cytokinetics during the 2nd quarter worth $13,216,000.

Insider Activity at Cytokinetics

In related news, CEO Robert I. Blum sold 36,601 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total value of $2,274,752.15. Following the completion of the transaction, the chief executive officer owned 430,330 shares of the company’s stock, valued at approximately $26,745,009.50. The trade was a 7.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Fady Ibraham Malik sold 12,033 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total transaction of $747,850.95. Following the completion of the transaction, the executive vice president directly owned 153,902 shares of the company’s stock, valued at $9,565,009.30. The trade was a 7.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 181,909 shares of company stock valued at $11,969,996. 2.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

CYTK has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Cytokinetics in a research report on Monday, April 20th. Stifel Nicolaus boosted their target price on shares of Cytokinetics from $98.00 to $108.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Royal Bank Of Canada lifted their price target on Cytokinetics from $101.00 to $119.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Wells Fargo & Company lifted their price target on Cytokinetics from $95.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Cytokinetics in a research note on Tuesday, March 10th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cytokinetics currently has a consensus rating of “Moderate Buy” and an average price target of $99.30.

Get Our Latest Stock Report on Cytokinetics

Cytokinetics Trading Down 0.3%

Shares of CYTK stock opened at $70.71 on Thursday. The firm has a 50-day moving average price of $69.55 and a 200 day moving average price of $65.87. Cytokinetics, Incorporated has a twelve month low of $31.52 and a twelve month high of $80.20. The company has a market capitalization of $8.80 billion, a price-to-earnings ratio of -10.34 and a beta of 0.42.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, meeting the consensus estimate of ($1.67). The firm had revenue of $19.36 million during the quarter, compared to analyst estimates of $8.52 million. During the same period in the previous year, the firm posted ($1.36) EPS. The company’s revenue for the quarter was up 1112.5% compared to the same quarter last year. As a group, research analysts predict that Cytokinetics, Incorporated will post -6.27 earnings per share for the current year.

About Cytokinetics

(Free Report)

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.